FR2732348B1 - Systeme d'expression conditionnel - Google Patents

Systeme d'expression conditionnel

Info

Publication number
FR2732348B1
FR2732348B1 FR9503841A FR9503841A FR2732348B1 FR 2732348 B1 FR2732348 B1 FR 2732348B1 FR 9503841 A FR9503841 A FR 9503841A FR 9503841 A FR9503841 A FR 9503841A FR 2732348 B1 FR2732348 B1 FR 2732348B1
Authority
FR
France
Prior art keywords
conditional expression
expression system
conditional
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9503841A
Other languages
English (en)
Other versions
FR2732348A1 (fr
Inventor
Laurent Bracco
Fabien Schweighoffer
Bruno Tocque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to FR9503841A priority Critical patent/FR2732348B1/fr
Priority to IL11771396A priority patent/IL117713A0/xx
Priority to TW085103937A priority patent/TW496873B/zh
Priority to ZA962506A priority patent/ZA962506B/xx
Priority to BR9607928A priority patent/BR9607928A/pt
Priority to AU54020/96A priority patent/AU716748B2/en
Priority to KR1019970706843A priority patent/KR19980703439A/ko
Priority to EP96911000A priority patent/EP0817845A1/fr
Priority to CZ973080A priority patent/CZ308097A3/cs
Priority to SK1311-97A priority patent/SK131197A3/sk
Priority to PCT/FR1996/000477 priority patent/WO1996030512A1/fr
Priority to JP8529022A priority patent/JPH11503011A/ja
Priority to HU9801221A priority patent/HUP9801221A3/hu
Priority to CA002214451A priority patent/CA2214451A1/fr
Publication of FR2732348A1 publication Critical patent/FR2732348A1/fr
Application granted granted Critical
Publication of FR2732348B1 publication Critical patent/FR2732348B1/fr
Priority to MXPA/A/1997/006928A priority patent/MXPA97006928A/xx
Priority to NO974449A priority patent/NO974449D0/no
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR9503841A 1995-03-31 1995-03-31 Systeme d'expression conditionnel Expired - Fee Related FR2732348B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR9503841A FR2732348B1 (fr) 1995-03-31 1995-03-31 Systeme d'expression conditionnel
TW085103937A TW496873B (en) 1995-03-31 1996-03-28 Bispecific chimeric molecule, nucleic acid sequence thereof, and in vitro expression system containing the same
ZA962506A ZA962506B (en) 1995-03-31 1996-03-28 Conditional expression system
IL11771396A IL117713A0 (en) 1995-03-31 1996-03-28 Gene expression system
SK1311-97A SK131197A3 (en) 1995-03-31 1996-03-29 Conditional expression system
KR1019970706843A KR19980703439A (ko) 1995-03-31 1996-03-29 조건 발현 시스템
EP96911000A EP0817845A1 (fr) 1995-03-31 1996-03-29 Systeme d'expression conditionnel
CZ973080A CZ308097A3 (cs) 1995-03-31 1996-03-29 Systém podmínění exprese
BR9607928A BR9607928A (pt) 1995-03-31 1996-03-29 Molécula quimérica biespecífica sequência de ácido nucléico sistema condicional de expressão de genes ácido nucléico vetor e composição farmacêutica
PCT/FR1996/000477 WO1996030512A1 (fr) 1995-03-31 1996-03-29 Systeme d'expression conditionnel
JP8529022A JPH11503011A (ja) 1995-03-31 1996-03-29 条件発現系
HU9801221A HUP9801221A3 (en) 1995-03-31 1996-03-29 Conditional expression system
CA002214451A CA2214451A1 (fr) 1995-03-31 1996-03-29 Systeme d'expression conditionnel
AU54020/96A AU716748B2 (en) 1995-03-31 1996-03-29 Conditional expression system
MXPA/A/1997/006928A MXPA97006928A (es) 1995-03-31 1997-09-11 Sistema de expresion condicional
NO974449A NO974449D0 (no) 1995-03-31 1997-09-26 Kondisjonelt ekspresjonssystem

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503841A FR2732348B1 (fr) 1995-03-31 1995-03-31 Systeme d'expression conditionnel

Publications (2)

Publication Number Publication Date
FR2732348A1 FR2732348A1 (fr) 1996-10-04
FR2732348B1 true FR2732348B1 (fr) 1997-04-30

Family

ID=9477639

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9503841A Expired - Fee Related FR2732348B1 (fr) 1995-03-31 1995-03-31 Systeme d'expression conditionnel

Country Status (15)

Country Link
EP (1) EP0817845A1 (fr)
JP (1) JPH11503011A (fr)
KR (1) KR19980703439A (fr)
AU (1) AU716748B2 (fr)
BR (1) BR9607928A (fr)
CA (1) CA2214451A1 (fr)
CZ (1) CZ308097A3 (fr)
FR (1) FR2732348B1 (fr)
HU (1) HUP9801221A3 (fr)
IL (1) IL117713A0 (fr)
NO (1) NO974449D0 (fr)
SK (1) SK131197A3 (fr)
TW (1) TW496873B (fr)
WO (1) WO1996030512A1 (fr)
ZA (1) ZA962506B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0872552A1 (fr) * 1997-04-15 1998-10-21 Leadd B.V. Véhicules de transfert de gènes exprimant la protéine VP2 induisant l'apoptose, et/ou l'apoptine
EP0878546A1 (fr) * 1997-04-15 1998-11-18 Leadd B.V. Véhicules de transfert de gènes exprimant la protéine VP2 induisant l'apoptose, et/ou l'apoptine
FR2775984B1 (fr) 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
FR2755144B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Fragments d'anticorps a chaine unique anti-p53 et utilisation
EP1717248A1 (fr) * 1997-06-04 2006-11-02 Oxford Biomedica (UK) Limited Vecteur contre les tumeurs
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US6479653B1 (en) * 1997-08-26 2002-11-12 Ariad Gene Therapeutics, Inc. Compositions and method for regulation of transcription
EP1040201A4 (fr) * 1997-11-28 2001-11-21 Invitrogen Corp Reactifs de fusion d'anticorps monoclonal a chaine unique regulant une transcription in vivo
FR2782732A1 (fr) * 1998-08-28 2000-03-03 Transgene Sa Systeme d'expression inductible
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
EP1242456B1 (fr) 1999-11-18 2008-10-15 Oxford Biomedica (UK) Limited Anticorps
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
AU2002349204A1 (en) * 2001-11-26 2003-06-10 University Health Network Self-assembling p53 peptides as gene delivery vehicles
DK1506288T3 (da) 2002-05-10 2013-07-22 Medical Res Council Aktiveringsinduceret deaminase (aid)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007936A1 (fr) * 1989-01-23 1990-07-26 Chiron Corporation Therapies de recombinaison pour infections et troubles hyperproliferatifs
EP0665883A1 (fr) * 1992-08-26 1995-08-09 Dnx Corporation Systeme de regulation binaire, a mediation par un represseur, qui utilise la tetracydine pour controler l'expression de genes chez les animaux transgeniques
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
ES2140359T1 (es) * 1993-06-14 2000-03-01 Basf Ag Control preciso de expresion genetica en celulas eucarioticas mediante promotores que responden a la tetaciclina.
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.

Also Published As

Publication number Publication date
SK131197A3 (en) 1998-05-06
BR9607928A (pt) 1998-06-09
AU5402096A (en) 1996-10-16
EP0817845A1 (fr) 1998-01-14
NO974449L (no) 1997-09-26
AU716748B2 (en) 2000-03-02
MX9706928A (es) 1997-11-29
FR2732348A1 (fr) 1996-10-04
CA2214451A1 (fr) 1996-10-03
HUP9801221A2 (hu) 1998-08-28
WO1996030512A1 (fr) 1996-10-03
CZ308097A3 (cs) 1998-01-14
ZA962506B (en) 1996-10-01
JPH11503011A (ja) 1999-03-23
KR19980703439A (ko) 1998-11-05
TW496873B (en) 2002-08-01
NO974449D0 (no) 1997-09-26
HUP9801221A3 (en) 1999-09-28
IL117713A0 (en) 1996-07-23

Similar Documents

Publication Publication Date Title
DE69525170D1 (de) System mit bedingtem zugang
DE69521063D1 (de) Befestigungssystem
DE69802540D1 (de) System mit bedingtem zugang
DE69514389T2 (de) Verbindungssystem
DE69611918D1 (de) Verbindungssystem
DE69615811D1 (de) Abbildungssystem
DE69617533D1 (de) Bilderzeugungssysteme
NO963577D0 (no) Video-forstörrelsesapparat
DE69610176D1 (de) Bildgebende Systeme
FR2732348B1 (fr) Systeme d'expression conditionnel
DE69634525D1 (de) Videoprozessor
DE69623742D1 (de) Bilderzeugungssystem
DE69636491D1 (de) Bilderzeugungssystem
ATA43196A (de) Pyrometallurgisches system
FR2725335B1 (fr) Systeme d'objectif d'imageur multiple
DE69603292D1 (de) Befestigungssystem
FR2742624B1 (fr) Systeme d'enregistrement audiovisuel
FR2769868B1 (fr) Systeme d'imprimante
FR2744260B1 (fr) Systeme d'automatisme securise
FR2743189B1 (fr) Systeme magnetique
FR2740495B1 (fr) Systeme de cloture
FR2736450B3 (fr) Systeme de telemedecine
FR2731258B1 (fr) Systeme d'embouts de raccordement
KR970020840U (ko) 내시경 시스템
KR970046198U (ko) 브이씨알을 이용한 전자 우편 시스템

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse